<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069428</url>
  </required_header>
  <id_info>
    <org_study_id>2021-438</org_study_id>
    <nct_id>NCT05069428</nct_id>
  </id_info>
  <brief_title>Delirium Reduction With Ramelteon</brief_title>
  <acronym>DREAM</acronym>
  <official_title>Delirium Reduction With Ramelteon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centennial Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centennial Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this study is to identify a medication that might treat and/or prevent&#xD;
      delirium in intensive care unit (ICU). Currently, there is no proven medical therapy for&#xD;
      prevention or treatment of delirium. Ramelteon is a medication approved for insomnia. We&#xD;
      hypothesize that ramelteon may help regulate the day/night cycle and decrease ICU delirium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melatonin is an endogenous hormone that regulates the sleep-wake cycle along with several&#xD;
      other physiological functions. It is reported that melatonin secretion may be impaired in ICU&#xD;
      patients, and there is some question whether this may be a contributing factor to delirium&#xD;
      occurrence. Ramelteon is a melatonin agonist with three to six times increased affinity for&#xD;
      MT1 and MT2 receptors versus melatonin. It is FDA approved for the treatment of insomnia, and&#xD;
      some studies suggested some benefit with ramelteon for delirium prevention. There is limited&#xD;
      prospective research data assessing the efficacy of ramelteon for delirium treatment. The&#xD;
      goal of this study therefore is to assess the efficacy of ramelteon versus placebo on the&#xD;
      prevention and treatment of delirium in ICU patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blinded, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive without delirium or coma in the ICU</measure>
    <time_frame>14 days</time_frame>
    <description>joint modeling approach taking account recurrence and terminating events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean daily Confusion Assessment Method -7 CAM-ICU-7 score</measure>
    <time_frame>14 days</time_frame>
    <description>Mean CAM-ICU-7 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delirium, as defined by a positive CAM-ICU-7</measure>
    <time_frame>14 days</time_frame>
    <description>Incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at 14 days from randomization or hospital discharge</measure>
    <time_frame>14 days</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of delirium, defined as number of days CAM-ICU positive</measure>
    <time_frame>14 days</time_frame>
    <description>Duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>14 days</time_frame>
    <description>LOS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">506</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>ramelteon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ramelteon 8 mg crushed tablet daily at 20:30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo powder equivalent grams at 20:30</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon 8mg</intervention_name>
    <description>administered crushed, orally at 20:30</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>ramelteon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medical or surgical ICU patient&#xD;
&#xD;
          -  Ability to take oral or nasogastric tube within 48 hours of admission to ICU&#xD;
&#xD;
          -  Expected ICU length of stay and life expectancy at least 48 hours&#xD;
&#xD;
          -  Patient or POA capable of signing informed consent within 48 hours of ICU admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past medical history includes cirrhosis&#xD;
&#xD;
          -  Active alcohol withdrawal&#xD;
&#xD;
          -  Patients taking fluvoxamine prior to admission&#xD;
&#xD;
          -  Self-reported hypersensitivity to ramelteon&#xD;
&#xD;
          -  Incarcerated patients&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Patients with acute neurological conditions including brain abscess, head bleed,&#xD;
             meningitis&#xD;
&#xD;
          -  Patients who are transferred from an outside hospital where they have resided for&#xD;
             greater than 4 days&#xD;
&#xD;
          -  Non-English speaking patients&#xD;
&#xD;
          -  Hearing-impaired patients requiring sign language for communication&#xD;
&#xD;
          -  Visually-impaired patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centennial Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Johnson, MD</last_name>
    <phone>214 604-8665</phone>
    <email>jennifer.johnson19@hcahealthcare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia Pate, PharmD</last_name>
    <phone>251 605-0991</phone>
    <email>patejul@gmail.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>September 25, 2021</last_update_submitted>
  <last_update_submitted_qc>September 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centennial Medical Center</investigator_affiliation>
    <investigator_full_name>Jennifer Johnson MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

